Oxford Nanopore expands compatibility with 10x Genomics to unlock deeper insights in single-cell transcriptomics
Expanded collaboration enables richer, more cost-effective biological insights from single cell workflows
Oxford Nanopore Technologies announced today its expanded collaboration with 10x Genomics, Inc. to enable seamless compatibility between their latest technologies, bringing more accurate, cost-effective and accessible insights to single-cell transcriptomics research.
The certified compatibility is between 10x Genomics’ latest Chromium Universal GEM-X 3’ and GEM-X 5’ single-cell chemistries — which enhance sensitivity while reducing cost per cell — and Oxford Nanopore’s high-accuracy V14 chemistry. This integration allows researchers to capture full-length isoforms and detect genetic variants at scale and with precision.
Oxford Nanopore has also released a major update to its EPI2ME single cell analysis workflow, enabling SNP calling across full-length transcripts. This enhancement simplifies the identification of disease-linked mutations, including those associated with cancer.
"One of the key applications of Oxford Nanopore sequencing from 10x Genomics libraries is the ability to detect SNPs that are missed by legacy sequencing technologies, because they fall outside the relatively small coverage region of short reads," said Chris Wright, Head of EPI2ME at Oxford Nanopore Technologies. "Our latest analysis update is designed to streamline SNP extraction from nanopore single cell sequence data.”
Advancing single-cell analysis
Single-cell analysis is transforming biomedical research, offering scientists a higher-resolution view of how genes are expressed in individual cells. The combined innovations from Oxford Nanopore and 10x Genomics bring:
● A more complete view of gene expression – by combining 10x Genomics’ single-cell profiling with Oxford Nanopore’s sequencing of any read length, researchers can accurately detect full-length RNA isoforms, capturing biological insights often missed with legacy technologies.
● Improved mutation detection – SNP calling in single-cell data makes it possible to identify genetic variants linked to diseases such as cancer.
● Simplified, cost-effective workflows – seamless compatibility means users of 10x Genomics’ platform can easily integrate Oxford Nanopore sequencing, including the ability to sequence long fragments into existing pipelines, reducing complexity and minimising time to discovery.
To support researchers using 10x Genomics’ Chromium Universal Gene Expression assays, both companies have collaborated to make datasets for two single-cell samples (Jurkat & 293T) available online.
This strengthened collaboration reinforces Oxford Nanopore’s leadership in a new era of full-length isoform sequencing in single-cell solutions. By providing real-time, high-resolution sequencing that integrates seamlessly with 10x Genomics’ high-throughput platforms, Oxford Nanopore continues to drive innovation in cancer research, neuroscience, immunology, and beyond.